Medical News: ECTRIMS: Cancer Drug Wins in Early MS Trial - in Meeting Coverage, ECTRIMS from MedPage Today
*Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
*Explain that a low-dose regimen of the leukemia drug alemtuzumab (Lemtrada) decreased annualized relapse rates in patients with newly diagnosed multiple sclerosis compared with interferon-beta-1a (Rebif).
*Note that alemtuzumab was no better than interferon in the other primary outcome measure, the proportion of patients showing sustained six-month accumulation of disability."
'via Blog this'